It does seem Tacked can get approvals for Fruzaqla wherever it wants….but what is key is the prices being negotiated for access to state funded healthcare systems. Spain was the first in the EU in December, the UK decision is due in early March. Only once these negotiations are complete will there be significant sales.
Takeda reports Oct-Dec sales on Thursday 30 Jan. The 2024 sales by quarter in USD were 50/80/75m. Q3 may be lowered by fewer hospital appts over the summer. Tak started sales in JPN and EU during H2, I am expecting a result in the 80-100m range with a bias towards 85-90m as most likely. |
A bit of news from Monday:
“Takeda Canada Reports Market Authorization For FRUZAQLA In Canada - Quick Facts
January 20, 2025 — 08:11 am EST”
More here; |
Last hour:
"Innovent Biologics ( HK:1801 -10.31% ▼ ) has issued an announcement.
Innovent Biologics has reported unusual price and trading volume movements in its shares but confirmed no changes in its business operations or any undisclosed information". |
Can but laugh - from yesterday's UK close to the price earlier, circa £230m wiped off the market cap. |
Followed by a near 10% fall in HK on no further news…. |
 Press Release
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
- Indication expands to include treatment-naïve patients -
- The 2021 conditional approval in previously treated patients converted to full approval -
Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alteration. The NMPA has also converted the prior conditional approval of ORPATHYS® in the previously treated patient population to full approval. The new label indication for ORPATHYS® will now include both treatment-naïve and previously treated patients in China. |
Trinity Delta today: HUTCHMED has secured divestment proceeds to advance its innovative pipeline, including its newly disclosed proprietary next-generation antibody-targeted therapy conjugate (ATTC) platform, through monetising a 45% equity interest in a non-core JV (joint venture). This divestment sharpens the focus onto HUTCHMED’s core business and will enable investment into the early-stage ATTC platform. Cash proceeds of c $608m provide additional financial flexibility as HUTCHMED executes on its goal of sustainable profitability from FY25 onwards. Funds will be directed towards progressing the Oncology/Immunology R&D pipeline – including ATTC assets – and supporting commercialisation of new and existing products in China. Ahead of deal close in Q125 our HUTCHMED valuation remains $5.94bn/£4.95bn/HK$46.31bn, equivalent to $34.07/ADS and 568p/HK$53.14 per share. |
Some good news to kick-start 2025 off: HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy |
Disappointingly they say it is all destined for pipeline development. |
And today a deal to dispose of SHPL has been announced for $608m.
Call on Tuesday, EGM required due to size of the transaction.
What will they do with this extra cash…..no fund raise was expected to deliver the pipeline….so it will likely mean M&A, or return to Shareholders (BB or divi?)
Shorts likely to run for the hills would be my guess and an opening jump in the share price on 2 Jan. |
Any ideas what the appointment of Cavendish means?
This is from the cavendish website
Cavendish is a trusted advisor to both public and private companies across various industry sectors. We deliver expert services in equity capital markets, M&A, debt advisory, and private growth capital. Our membership of Oaklins, the world’s foremost mid-market mergers and acquisitions advisor, gives us access to 60 offices in 40 countries, ensuring unparalleled global coverage.
We specialise in providing our clients with access to equity, debt, and alternative financing, as well as offering cross-border M&A advice. Our extensive experience, drive, and proactive approach make Cavendish the ideal partner for ambitious companies. |
Good news again. Will it have any effect on the share price?
Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR21;) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. |
HCM deserves more than the only +4p of the day, even after also recovering from a poor opening.
Folks will surely catch on as the days go by, if they have the insight.
f |
An early gift from the Chinese regulator giving conditional approval for Fruq + Sintilimab (another Lilly development with Innovent).
Q what will the commercial strategy be for this combination
Q what will Takeda do? It has its own PD-1 if it does not want to use Sintilimab.
The company launch runway had this one ahead of Sovlep despite Sov being submitted three months earlier….I am expecting Sovlep, Taz and Savo approvals about 1 year to 15m after submission. Hopefully Sovlep comes in Q1 25. |
A nice modest uptick into the close today.
f |
Just more sellers than reasons to buy. Markets looking toppy, more negative economic news from China. Probably nothing hcm specific. |
What a differenve a week can make ... any thoughts on why the steady drift downwards?
f |
Looking very good for the going forward.
f |
Good news from HCM today: HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
They also received a milestone payment from Takeda as a consequence. |
Reason for today's rise is perhaps due to the RNS release of only a very short time ago.
Woiuld appear to be a quite significat appointment.
f |
Nice 6.5% uptick at the start of today.
Bid/Ask totals 21.2k v 17.9k, as I type.
f |
Good entry point. |
Took some again today at near 265p.
The last lot did well and forecasts appear enthusiastic for the going forward, with a recent tp of 539p.
Good wishes to all.
f |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
